Pay in 4 interest-free payments of $6.50 Learn more
Ships within 48 hours · Estimated delivery Jul 27 - Aug 1
The most commonly observed side effects include mild injection-site irritation and nausea, which subside within the first week or two, especially at lower doses
Such local side effects are usually transient and self-limited
Safety and Research Limitations Importantly, No adequate clinical evidence defines safe human exposure, maximum tolerated dose, reproductive toxicity, carcinogenicity, genotoxicity, cardiovascular risk, liver safety, kidney safety, endocrine effects, or drug interactions
INHIBIDORES DEL RECEPTOR DEL FACTOR DE CRECIMIENTO EPIDRMICO: PANITUMUMAB (VECTIBIX), CETUXIMAB (ERBITUX), ERLOTINIB (TARCEVA), GEFITINIB (IRESSA) Y LAPATINIB (TYVERB) El receptor del factor de crecimiento epidrmico (EGFR) pertenece a la familia de los receptores del factor de crecimiento epidrmico humano (HER), a la que pertenecen otros tres receptores transmembrana (HER2/neu, HER-3 y HER-4)
The results are not directly comparable because the peptides are not equivalent products
DISCLAIMER This product is intended for laboratory research use only
US$ 25.90
US$ 20.43
US$ 25.18
US$ 22.51